DE69532475D1 - Krebs hemmende peptide - Google Patents

Krebs hemmende peptide

Info

Publication number
DE69532475D1
DE69532475D1 DE69532475T DE69532475T DE69532475D1 DE 69532475 D1 DE69532475 D1 DE 69532475D1 DE 69532475 T DE69532475 T DE 69532475T DE 69532475 T DE69532475 T DE 69532475T DE 69532475 D1 DE69532475 D1 DE 69532475D1
Authority
DE
Germany
Prior art keywords
cancer
inhibiting peptides
peptides
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69532475T
Other languages
English (en)
Other versions
DE69532475T2 (de
Inventor
George R Pettit
Jayaram K Srirangam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University ASU
Original Assignee
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University ASU filed Critical Arizona State University ASU
Publication of DE69532475D1 publication Critical patent/DE69532475D1/de
Application granted granted Critical
Publication of DE69532475T2 publication Critical patent/DE69532475T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69532475T 1994-11-10 1995-11-06 Krebs hemmende peptide Expired - Fee Related DE69532475T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US338004 1994-11-10
US08/338,004 US5599902A (en) 1994-11-10 1994-11-10 Cancer inhibitory peptides
PCT/US1995/014379 WO1996014856A1 (en) 1994-11-10 1995-11-06 Cancer inhibitory peptides

Publications (2)

Publication Number Publication Date
DE69532475D1 true DE69532475D1 (de) 2004-02-26
DE69532475T2 DE69532475T2 (de) 2004-11-11

Family

ID=23322987

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532475T Expired - Fee Related DE69532475T2 (de) 1994-11-10 1995-11-06 Krebs hemmende peptide

Country Status (7)

Country Link
US (1) US5599902A (de)
EP (1) EP0787009B1 (de)
JP (1) JPH10509147A (de)
AU (1) AU4230896A (de)
CA (1) CA2203694C (de)
DE (1) DE69532475T2 (de)
WO (1) WO1996014856A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
ATE284412T1 (de) * 1998-01-09 2004-12-15 Univ Arizona State Anti-kryptokokkus peptide
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2006071441A2 (en) 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
EP1883627B1 (de) 2005-05-18 2018-04-18 Pharmascience Inc. An die bir-domäne bindende verbindungen
US8039273B2 (en) 2005-07-18 2011-10-18 Seattle Genetics, Inc. β-glucuronide-linker drug conjugates
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CR20190516A (es) 2007-07-16 2020-02-18 Genentech Inc ANTICUERPOS ANTI-CD79B E INMUNOCONJUGADOS (Divisional 2015-0040)
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
EP3115469B1 (de) 2007-11-19 2020-04-29 Celera Corporation Lungenkrebsmarker und verwendungen davon
EP2244729B1 (de) 2008-01-18 2016-11-02 MedImmune, LLC Cystein-manipulierte antikörper zur stellenspezifischen konjugation
CN101981055B (zh) 2008-01-31 2016-03-09 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
MX2012003198A (es) 2009-10-23 2012-06-12 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados.
EP2510011B2 (de) 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale B7h6 -bindende monoklonale antikörper und ihre verwendung
MX2012008884A (es) 2010-02-08 2012-08-31 Agensys Inc Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
AR081750A1 (es) 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
CN108524510A (zh) 2011-05-16 2018-09-14 皇家飞利浦有限公司 生物正交药物活化
EP2710040B1 (de) 2011-05-19 2017-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3-antikörper und deren verwendungen
BR112013030372A2 (pt) * 2011-05-27 2016-08-30 Ambrx Inc composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural
JP5926374B2 (ja) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
JP6120833B2 (ja) 2011-06-22 2017-04-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
AU2012338436B2 (en) 2011-11-17 2015-09-03 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP4406612A3 (de) 2012-06-19 2024-10-16 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
IN2015DN00552A (de) 2012-07-19 2015-06-26 Redwood Bioscience Inc
EP3494996A1 (de) 2012-08-23 2019-06-12 Agensys, Inc. An 158p1d7-proteine bindende antikörperwirkstoffkonjugate
JP6826367B2 (ja) 2012-08-31 2021-02-03 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
JP6089108B2 (ja) 2012-09-20 2017-03-01 セルトリオン， インク． ドラスタチン１０誘導体、その製造方法およびそれを含む抗癌剤組成物
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
EP4245744A3 (de) 2012-11-22 2024-05-01 Tagworks Pharmaceuticals B.V. Chemisch spaltbare gruppe
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2931316B1 (de) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxylpolymer-heilmittelproteinkonjugate
BR112015023520A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc purificação do conjugado de anticorpo-fármaco (adc)
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
TWI689313B (zh) 2013-03-15 2020-04-01 德商艾伯維德國有限及兩合公司 抗-ｅｇｆｒ抗體藥物結合物調配物
EP3019522B1 (de) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
SG11201600587VA (en) 2013-08-01 2016-02-26 Agensys Inc Antibody drug conjugates (adc) that bind to cd37 proteins
EP3044236A2 (de) 2013-09-12 2016-07-20 Halozyme, Inc. Modifizierte anti-egfr-antikörper und verfahren zur verwendung davon
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
EP3054991B1 (de) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
SG11201605260VA (en) 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10323083B2 (en) 2014-01-15 2019-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that specifically bind matrilin-3 and their use
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
TWI684600B (zh) 2014-03-21 2020-02-11 美商艾伯維有限公司 抗－ｅｇｆｒ抗體及抗體藥物結合物
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3177320B1 (de) 2014-07-31 2021-01-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Humane monoklonale antikörper gegen epha4 und deren verwendung
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
SG11201707195SA (en) 2015-03-09 2017-10-30 Agensys Inc Antibody drug conjugates (adc) that bind to flt3 proteins
EP3091033A1 (de) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3-antikörper und verwendungen davon
EP3295171A1 (de) 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und kits zur markierung, zum nachweis und zur isolierung von foxp3+-regulierenden t-zellen, isolierten populationen von foxp3+-regulierenden t-zellen und verwendungen davon
JP6770533B2 (ja) 2015-05-22 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃａｔｈ−Ｄの触媒活性と、そのＬＲＰ１レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
WO2016189091A1 (en) 2015-05-26 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
EP4286511A3 (de) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Verfahren zur behandlung von krebs mit veränderten t-zellen
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR101839186B1 (ko) 2015-09-03 2018-03-15 경상대학교산학협력단 망막세포 재생효과를 갖는 군소 추출물의 용도
AU2016335750B2 (en) 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
AU2016335848B2 (en) 2015-10-09 2020-12-17 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2017064034A1 (en) 2015-10-12 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
EP3373977A4 (de) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University Zellenpenetrierende, guanidiniumreiche oligophosphotriester zur wirkstoff- und sondenfreisetzung
CN114796520A (zh) 2016-01-27 2022-07-29 苏特罗生物制药公司 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
US11191821B2 (en) 2016-02-27 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptide vaccine formulations and use thereof for inducing an immune response
EP3423112A4 (de) 2016-02-29 2020-02-26 Madrigal Pharmaceuticals, Inc. Hsp9-inhibitor-wirkstoff-konjugate
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2017186140A1 (zh) * 2016-04-28 2017-11-02 江苏恒瑞医药股份有限公司 一种制备酪氨酸激酶抑制剂及其衍生物的方法
HUE057856T2 (hu) 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
LT3458479T (lt) 2016-06-08 2021-02-25 Abbvie Inc. Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
EP3507304B1 (de) 2016-09-02 2024-04-03 Lentigen Technology, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mit duocars
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN117946283A (zh) 2017-01-09 2024-04-30 莱蒂恩技术公司 用于用抗间皮素免疫治疗癌症的组合物和方法
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
EP3601356A1 (de) 2017-03-24 2020-02-05 Lentigen Technology, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd33-immuntherapie
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
AU2018309735A1 (en) 2017-07-31 2020-02-20 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019055842A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD19 IMMUNOTHERAPY
EP3684814A1 (de) 2017-09-18 2020-07-29 Sutro Biopharma, Inc. Anti-folat-rezeptor-alpha-antikörperkonjugate und ihre verwendung
CN111629735B (zh) 2017-10-16 2024-05-17 莱蒂恩技术公司 用于用抗cd22免疫治疗来治疗癌症的组合物和方法
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
JP7377802B2 (ja) 2017-12-20 2023-11-10 レンティジェン・テクノロジー・インコーポレイテッド 免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
EP3788032B1 (de) 2018-05-04 2024-01-24 Tagworks Pharmaceuticals B.V. Verbindungen mit einem linker zur erhöhung der transcyclooctenstabilität
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
CA3101469A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
EP3820909B1 (de) 2018-07-11 2023-03-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoklonaler antikörper zum nachweis des antiviralen arzneimittels emtricitabin (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidin)
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
JP7546554B2 (ja) 2018-09-26 2024-09-06 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
JP2022513400A (ja) 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
AU2019387377A1 (en) 2018-11-30 2021-06-17 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD38 immunotherapy
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
CA3132660A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
AU2020283027A1 (en) 2019-05-30 2021-12-23 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
JP2022537543A (ja) 2019-06-17 2022-08-26 タグワークス ファーマシューティカルス ビー．ブイ． 高速で且つ効率的なクリック放出の為の化合物
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4167995A4 (de) 2020-06-18 2024-09-11 Univ Leland Stanford Junior Isoformspezifische aldehyddehydrogenaseinhibitoren
CA3171101A1 (en) 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
JP2023542678A (ja) 2020-09-21 2023-10-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症状態の処置のための抗ｃｄ４０抗体の使用。
JP2023548555A (ja) 2020-11-05 2023-11-17 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
JP2024527551A (ja) 2021-06-29 2024-07-25 シージェン インコーポレイテッド 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法
EP4399283A2 (de) 2021-09-06 2024-07-17 Veraxa Biotech GmbH Neue aminoacyl-trna-synthetase-varianten zur genetischen codeerweiterung in eukaryoten
EP4186529A1 (de) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
WO2023094525A1 (en) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4314031B1 (de) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Maskiertes il12-protein
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024044743A1 (en) 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en) 2023-03-10 2024-09-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
WO2024197151A2 (en) 2023-03-22 2024-09-26 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
SG67935A1 (en) * 1992-12-16 1999-10-19 Basf Ag Novel peptides the preparation and use thereof
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
JPH10509147A (ja) 1998-09-08
CA2203694C (en) 2000-11-21
EP0787009B1 (de) 2004-01-21
AU4230896A (en) 1996-06-06
EP0787009A1 (de) 1997-08-06
US5599902A (en) 1997-02-04
CA2203694A1 (en) 1996-05-23
DE69532475T2 (de) 2004-11-11
EP0787009A4 (de) 1999-09-22
WO1996014856A1 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
DE69532475D1 (de) Krebs hemmende peptide
DE4393381T1 (de) Peptide
DE69332485D1 (de) Immunmodulierende peptide
DE69129395D1 (de) Antimikrobielle Peptide
DE69427370D1 (de) Neue integrinbindende peptide
ATE212643T1 (de) Neue isosterische peptide
DK0845003T3 (da) Hidtil ukendte opioid-peptider
NO942066D0 (no) Peptidderivater
DE69615171D1 (de) Nitrosylierte neuropeptide
DK6893D0 (da) Peptid
NO985680D0 (no) Peptidderivater
LV10962A (lv) Jauni peptidi
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
NO983849L (no) Peptidderivater
BR9508433A (pt) Peptídeos
FI940109A0 (fi) Peptidejä
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
FI970744A0 (fi) Uusia immuuniehkäiseviä peptidejä
NO981051D0 (no) Peptidderivater
NO932237D0 (no) Lineaere peptider
MA22717A1 (fr) Peptides hemoregulateurs
ATE277076T1 (de) Antineoplastische peptide
FI950211A0 (fi) Huokosia muodostavia peptidejä Geolycosa riograndesta

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee